Binimetinib Improves Upon Efficacy of Encorafenib in BRAF-Mutant Melanoma
Source: Cancer Therapy Advisor, August 2023
Adding binimetinib to treatment with encorafenib improves efficacy in patients with BRAFV600-mutant melanoma, according to trial results published in the Journal of Clinical Oncology.
These results, from the phase 3 COLUMBUS trial, confirm that binimetinib contributes to the efficacy of the combination, which has been approved by the US Food and Drug Administration (FDA) for BRAFV600-mutant unresectable or metastatic melanoma.
In the first part of the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453), treatment with encorafenib at 450 mg daily and binimetinib at 45 mg twice a day improved progression-free survival (PFS) over monotherapy with either vemurafenib at 960 mg twice a day or encorafenib at 300 mg daily. These results led to the FDA approval of binimetinib in combination with encorafenib.